Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has scheduled a board meeting on October 29, 2026, to consider and approve un-audited financial results for the quarter and half year ended September 30, 2026.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Essix Biosciences Ltd & Others.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has received a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, from Essix Biosciences Limited, indicating the acquisition of 14,00,000 equity shares of the company through the conversion of Fully Convertible Warrants.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has informed about the outcome of the Preferential Issue Committee meeting, where 14,00,000 equity shares were allotted upon conversion of 14,00,000 fully convertible warrants to Essix Biosciences Limited, a promoter group entity, at an issue price of ₹196/- per warrant.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced a special window for the re-lodgement of physical shares and dematerialisation, in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated January 30, 2026.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced the voting results of its 31st Annual General Meeting (AGM), which was held on September 30, 2026. The meeting saw the passing of four resolutions, including the adoption of audited financial statements for the year ended March 31, 2026, and the appointment of a new director. The voting results show that 98.51% of votes were in favour of the resolutions.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has received a compliance certificate from Alankit Assignments Ltd, its Registrar and Share Transfer Agent, under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September, 2026.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd held its 31st Annual General Meeting (AGM) on September 30, 2026, through video conferencing. The meeting was attended by 47 shareholders and the requisite quorum was present. The AGM approved the audited financial statements for the financial year ended March 31, 2026, and appointed a new director in place of Navrattan Munjal.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has issued an intimation to shareholders to furnish PAN, KYC details, and nomination details as per SEBI Master Circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024. Shareholders who have not updated their details will not be eligible to lodge grievances or avail services from the company's RTA.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced the closure of its trading window for all insiders, including promoters, directors, and key management personnel, from October 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter and half year ended September 30, 2026.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced a schedule for an analyst/investor meet on September 29, 2026, at 1:00 PM IST, to be held in virtual mode. The meeting is subject to change due to exigencies.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Essix Biosciences Ltd and others.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has published a newspaper advertisement regarding the notice of its 31st Annual General Meeting, details of e-voting, dispatch of the notice of AGM and Annual Report, and the availability of the Annual Report for the financial year 2025-26 on its website and stock exchanges.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced its Annual Report for FY 2025-26, along with the Notice convening the 31st Annual General Meeting (AGM) to be held on September 30, 2026. The company has fixed September 23, 2026, as the Cut-Off Date for determining member entitlement to cast votes at the AGM.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced the holding of its 31st Annual General Meeting through Video Conference (VC) / Other Audio-Visual Means (OAVM) on September 30, 2026.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced the outcome of its Preferential Issue Committee meeting, where the committee has taken note of the revised valuation report and made changes to the Explanatory Statement to the Extra-Ordinary General Meeting Notice. The company has decided to issue warrants at an issue price of Rs. 196/- each, which is higher than the minimum issue price of Rs. 195.98/- each.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced the outcome of its Board Meeting held on September 02, 2026, where the Board approved the appointment of Mr. Amit Mathur as Additional Director, reconstituted the Audit Committee, and made other announcements.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has responded to BSE Surveillance's query regarding the sudden increase in volume of its shares, stating that the company has made all necessary disclosures and is not aware of any specific reason for the spurt in volume/price.

Ind-Swift Laboratories Ltd

The BSE has sought clarification from Ind-Swift Laboratories Ltd regarding a movement in volume on August 27, 2026, and is awaiting a response.

Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Ltd has announced its Q1 FY27 earnings, with a strong quarter of performance, both operationally and financially. The company has commercialized new products, expanded its CDMO partnerships, and seen growth in its export business.